Avidity Biosciences (RNA) said Monday that topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed "consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase."
The biopharmaceutical company said del-zota also demonstrated favorable safety and tolerability in the dose cohorts. It also said it will present the data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference this week.
Shares of Avidity Biosciences were up 2.9% in recent premarket activity.
Price: 32.00, Change: +0.89, Percent Change: +2.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.